Ferasirrox Tablet 500 mg contains Deferasirox, a potent oral iron chelator used to manage chronic iron overload. Iron overload can occur in patients requiring frequent blood transfusions, such as those with thalassemia major, sickle cell disease, or myelodysplastic syndromes, leading to excessive accumulation of iron in vital organs like the liver, heart, and endocrine glands. Uncontrolled iron overload can cause severe complications, including cardiomyopathy, liver cirrhosis, and hormonal dysfunction.
Ferasirrox Tablet 500 mg works by binding excess iron in the bloodstream, forming a complex that is excreted through the feces. This reduces iron levels in the body, preventing organ damage and supporting long-term health in patients requiring chronic transfusion therapy. The once-daily oral tablet offers a convenient and effective alternative to traditional parenteral chelation therapies, improving patient compliance and quality of life.
রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন
Active Ingredient:
Deferasirox 500 mg per tablet
Effective Iron Chelation:
Binds and removes excess iron from the body
Reduces transfusion-related iron overload
Protects vital organs, including the heart and liver
Convenient Oral Therapy:
Once-daily tablet for easy administration
Avoids the need for invasive intravenous chelation
Supports better adherence and long-term management
Organ Protection:
Prevents complications related to iron-induced organ damage
Helps maintain cardiac, hepatic, and endocrine function
Supports improved survival and quality of life
Customizable Dosing:
Dose can be tailored according to body weight, transfusion history, and serum ferritin levels
Regular monitoring ensures optimal therapeutic outcomes
Deferasirox, the active component of Ferasirrox, is a tridentate iron chelator, meaning one molecule binds to one atom of iron. Its mechanism includes:
Iron Binding: Selectively binds free iron (Fe³⁺) in the bloodstream and tissues.
Complex Formation: Forms a stable, water-soluble iron-deferasirox complex.
Excretion: Eliminates excess iron through the fecal route, lowering systemic iron levels.
Through these actions, Ferasirrox helps prevent organ damage caused by iron accumulation, a major risk in transfusion-dependent patients.
Ferasirrox Tablet 500 mg is indicated for:
Treatment of chronic iron overload in patients with thalassemia major
Management of iron overload in sickle cell disease and myelodysplastic syndromes
Patients receiving regular blood transfusions who are at risk of iron-induced organ damage
Long-term prevention of cardiac, hepatic, and endocrine complications due to iron accumulation
Take once daily as prescribed by a healthcare professional.
Swallow the tablet whole with water, preferably on an empty stomach or at least 30 minutes before food.
Dosage is individualized based on body weight, transfusion history, and serum ferritin levels.
Regular monitoring of serum ferritin, liver function, and kidney function is recommended during therapy.
Do not abruptly stop therapy, as it may lead to rapid iron accumulation.
Inform your doctor if you have kidney disease, liver impairment, gastrointestinal disorders, or hypersensitivity to Deferasirox.
Common side effects include nausea, vomiting, diarrhea, abdominal pain, rash, and headache.
Rare but serious effects may include kidney or liver toxicity, cytopenias, and gastrointestinal bleeding. Immediate medical attention is required if severe symptoms occur.
Adequate hydration is recommended to minimize kidney-related complications.
Avoid self-adjusting the dose without medical guidance.
Store at room temperature below 30°C in a dry place.
Protect the tablets from light and moisture.
Keep out of reach of children.
Ferasirrox Tablet 500 mg provides a safe, convenient, and effective solution for managing chronic iron overload. By binding and eliminating excess iron, it prevents organ damage, improves long-term health, and enhances quality of life in patients requiring regular transfusions.
Login Or Registerto submit your questions to seller
No none asked to seller yet